Browse Reports

NIKA PHARMACEUTICALS, INC. is a pharmaceutical company incorporated in Colorado in 2000. The company has shifted its business focus to production and distribution of pharmaceutical products and dietary supplements through exclusive rights agreements. Key products include Thymus Nuclear Glycoprotein (TNG), which has clinical trial history related to HIV treatment, and dietary supplements Carotilen and Physiolong. NIKA has strategic partnerships and joint business agreements to develop and distribute medicinal products based on patented technologies. The company merged with Nika BioTechnology, Inc. in 2024, consolidating its ownership in Nika Europe, Ltd., which is preparing to build a pharmaceutical manufacturing facility. NIKA’s common stock is listed on OTCQB under the ticker NIKA. Financially, the company reported no revenue for fiscal year 2024 and a net loss for fiscal year 2025, with limited liquidity as of the end of 2025. The company operates with a small executive team and has not yet adopted formal insider trading policies.

PFS Bancorp, Inc. was incorporated in 2023 as the holding company for Peru Federal Savings Bank following its conversion to a stock organization. The company operates primarily in LaSalle County, Illinois, and surrounding areas, focusing on deposit gathering and lending, mainly one- to four-family residential mortgage loans. The loan portfolio also includes commercial real estate, commercial loans, and other loan types. The company is regulated by the Federal Reserve Board, OCC, and FDIC, and offers electronic banking services. It faces competition from various financial institutions in its market area.

KAANAPALI LAND LLC is a Delaware limited liability company focused on land investment and development on Maui, Hawaii. The company operates two main business segments: Property, which involves land sales, development, and leasing; and Agriculture, which includes coffee farming, milling, and related sales. Revenue recognition for property sales occurs at closing, while agricultural and other revenues are recognized upon transfer of goods or services. The company has been impacted by the Lahaina wildfires, resulting in property damage and related insurance claims. Financial statements indicate ongoing net losses and significant expenses related to rebuilding and operations.

Fidelity Solana Fund (the Trust) is an exchange-traded product formed as a Delaware Statutory Trust in March 2025 and commenced operations in November 2025. The Trust issues common shares listed on NYSE Arca, representing fractional undivided beneficial interest in the Trust's holdings of SOL, the native token of the Solana blockchain. The Trust's investment objective is to track the performance of SOL as measured by the Fidelity Solana Reference Rate (the Index), adjusted for expenses and liabilities, plus staking rewards. The Trust holds SOL directly, with all tokens held by qualified Custodians. The Sponsor manages the Trust passively without leverage or derivatives and utilizes staking activities through trusted node operators to generate staking rewards, which are shared with the Trust net of fees. The Trust sells and redeems shares in blocks of 25,000 shares (Baskets) based on the SOL attributable to each share. The Trust provides investors with access to SOL through traditional brokerage accounts without the risks of direct SOL ownership or transfer. The Trust's NAV is calculated daily using the Index price methodology, which is a volume-weighted median price composite from eligible spot markets. The Sponsor charges an annual fee of 0.25% of SOL holdings, with a fee waiver for the first six months after commencement, and the Trust bears a 15% staking fee. The Trust reported a net loss of $6.1 million for the fiscal year ended December 31, 2025.

FVCBankcorp, Inc. operates as a bank holding company with its sole subsidiary, FVCbank, a community-oriented commercial bank headquartered in Fairfax, Virginia. The bank serves small and medium-sized businesses, nonprofit organizations, professionals, and individual customers primarily in the Washington, D.C. and Baltimore metropolitan areas. The company has grown organically and through acquisitions since its inception in 2007. It offers a wide range of banking services including commercial and retail banking, digital and mobile banking, treasury management, insurance, and merchant services. Lending products focus on commercial real estate, commercial construction, government contract financing, SBA loans, home equity loans, and consumer loans. The company manages credit risk through underwriting, portfolio monitoring, and an allowance for credit losses based on peer data and economic forecasts. The company reported net income of $22.06 million and EPS of $1.22 for fiscal 2025 [S1][S2].

Horizon Quantum Holdings Ltd. operates in the emerging quantum computing industry, developing software infrastructure aimed at enabling practical applications of quantum hardware. The company’s business model depends on achieving quantum advantage and establishing strategic collaborations with hardware vendors. Its customer base primarily includes governmental agencies, large enterprises, and research institutions, which typically have longer sales cycles. Horizon Quantum completed a Business Combination with dMY Squared Technology Group, Inc. in March 2026, raising significant capital through SAFEs and a PIPE private placement. The company is headquartered in Singapore and files annual reports on Form 20-F with the SEC as a foreign private issuer [S1][S2].

EWSB Bancorp, Inc. is a Maryland-based public company owning East Wisconsin Savings Bank, a Wisconsin-chartered stock savings bank with headquarters in Kaukauna and branches in Appleton, Freedom, and Kimberly, Wisconsin. The bank's core business involves accepting deposits and originating loans, primarily one- to four-family residential real estate loans, which constitute the majority of its loan portfolio. Other loan types include marine and recreational vehicle loans, construction loans, home equity loans and lines of credit, commercial loans, and other consumer loans. The bank also invests in securities such as U.S. Treasury and federal agency securities and corporate bonds. The company completed its IPO in September 2024, raising approximately $7.5 million. It operates under comprehensive regulation by the Federal Reserve Board, Wisconsin Department of Financial Institutions, and the FDIC. The primary lending market is Outagamie County, Wisconsin, and adjoining counties, an area with a diverse economic base. The company faces competition from a range of financial institutions including large banks, community banks, credit unions, and fintech firms.

Park Dental Partners, Inc. operates as a dental resource organization (DRO) providing business support services such as staffing, facilities, equipment, billing, marketing, and administrative functions to affiliated dental practices. The affiliated practices deliver both general and specialty dental services under long-term agreements, primarily in Minnesota, Wisconsin, and Arizona. The company’s network includes 214 dentists and 990 supporting clinical and administrative personnel across 86 locations. The business model is dentist-majority owned, with affiliated dentists having governance rights and active operational involvement. The company has grown through acquisitions and organic expansion, with revenues of $244.5 million in 2025. The U.S. dental services industry is characterized by fragmentation, consumer-driven payment models, and increasing insurance coverage. Park Dental Partners leverages centralized management and economies of scale to support affiliated practices and enhance patient care and operational efficiency.

Lucid Diagnostics Inc. develops and commercializes diagnostic technology aimed at early detection of esophageal adenocarcinoma (EAC) and its precursors in patients with gastroesophageal reflux disease (GERD). Its flagship product, EsoGuard, is a DNA methylation assay performed on esophageal cells collected non-invasively using the EsoCheck device. EsoGuard and EsoCheck are FDA 510(k)-cleared and CE Mark certified, and are based on patented technology licensed from Case Western Reserve University. The company targets a large U.S. market of approximately 30 million at-risk patients recommended for screening by clinical guidelines. EsoGuard is endorsed by major gastroenterology societies as an alternative to invasive endoscopy for Barrett's Esophagus screening. Lucid commercializes its products through owned and satellite test centers, mobile units, telemedicine, and direct contracting with employers and health systems. It has secured Medicare payment and is actively pursuing expanded coverage. Clinical utility and validity are supported by multiple studies and ongoing NIH- and DOD-funded trials. Manufacturing capacity for EsoCheck is scalable through established partners. Financially, the company reported $1.21 million revenue for Q3 2025 and a net loss of $58.0 million for fiscal 2025, with a strong cash position as of September 2025.

Precigen, Inc. operates in the biotechnology sector, specializing in precision medicine by leveraging synthetic biology technologies to develop gene and cell therapies. The company utilizes proprietary platforms such as UltraVector, AdenoVerse, and UltraCAR-T to design and deliver multigenic gene programs aimed at treating complex diseases. Its clinical pipeline includes lead candidates like Papzimeos, approved for recurrent respiratory papillomatosis (RRP), with regulatory designations and ongoing market access initiatives. Precigen maintains internal manufacturing capabilities and has established commercial supply agreements to support product production. The company manages a senior secured term loan facility to fund operations and development. Its strategy emphasizes financial discipline, active portfolio management, rapid execution, and strategic partnerships to advance its pipeline and commercial products [S1][S17][S20].

SeaStar Medical Holding Corp develops and commercializes the Selective Cytopheretic Device (SCD) therapy, a disease-modifying extracorporeal device that targets activated neutrophils and monocytes to reduce destructive hyperinflammation (cytokine storm) in critically ill patients. The therapy has FDA Humanitarian Device Exemption approval for pediatric acute kidney injury (AKI) patients with sepsis requiring kidney replacement therapy, marketed as QUELIMMUNE. The company is conducting a pivotal clinical trial (NEUTRALIZE-AKI) for adult AKI patients receiving continuous renal replacement therapy (CRRT). The SCD therapy integrates into existing CRRT systems using regional citrate anticoagulation to create a low calcium environment that modulates immune cells without causing immunosuppression. SeaStar holds multiple FDA Breakthrough Device Designations for various adult indications and is expanding clinical development into additional acute and chronic inflammatory conditions. The company uses a direct sales model for pediatric therapy and is developing reimbursement strategies for adult indications. SeaStar faces operational and financial challenges, including recurring losses, the need for additional capital, and regulatory approval risks.

Marpai, Inc. operates as a technology platform company offering healthcare administrative services to self-insured employers in the United States. Its subsidiaries provide Third Party Administrator (TPA) services, Pharmacy Benefit Management (PBM), and value-oriented health plan services. The company primarily serves small and medium-sized enterprises and local government entities. Marpai's core offerings include health plan administration services such as claims adjudication, member support, provider network access, and stop-loss insurance sourcing. Ancillary services include clinical care management, pharmacy savings programs, and repricing of out-of-network claims. The company leverages deep learning and data analytics to improve healthcare outcomes and reduce costs, supported by an in-house clinical team and a mobile app for members. Marpai operates in a highly regulated environment with compliance obligations under federal and state healthcare laws. The market is competitive with many regional and national players. The company reported $18.1 million in revenue and a net loss of $16.6 million for the fiscal year ended December 31, 2025, with liquidity constraints and ongoing strategic reviews.

Dakota Gold Corp. was incorporated in 2017 and focuses on acquiring, exploring, and developing gold mineral properties in the Homestake District of South Dakota, USA. The company owns over 49,500 acres of mineral claims and leases in this historically productive gold district. It operates solely in the mineral exploration and evaluation segment and has not commenced mining or generated revenues. The company leverages extensive management and technical experience, including decades of expertise in the Homestake District, to advance its projects using modern exploration techniques and geophysical surveys. Key projects include the Richmond Hill and Maitland properties, with ongoing drilling programs and permitting activities. The company aims to move projects from exploration to development and production as exploration results dictate [S1][S2][S6].

Exicure, Inc. was historically focused on developing nucleic acid therapies targeting RNA but suspended all R&D activities in 2022 and sold its biotechnology intellectual property in 2024. The company is now focused on exploring strategic alternatives including acquisitions and partnerships, with a notable acquisition of GPCR Therapeutics USA Inc. in 2025. GPCR USA's Phase 2 clinical trial for a CXCR4 inhibitor in Multiple Myeloma completed in early 2026, marking a key milestone. Exicure has no current product revenue and continues to incur operating losses, relying on cash reserves and financing to support operations. The company faces liquidity constraints and Nasdaq listing compliance risks. Significant stockholders hold substantial influence over corporate governance.

CATO CORP is a publicly traded company that reported fiscal year 2025 financial results in a 10-K filing dated March 25, 2026. The company generated $653.8 million in revenue but incurred a net loss of $5.9 million for the year ending January 31, 2026. Liquidity metrics indicate a current ratio of 1.24 and a cash ratio of 0.47, reflecting moderate short-term financial flexibility. Recent quarterly news reports describe a pattern of narrowing losses year over year, driven in part by same-store sales growth and margin improvements, although revenue declines and operational challenges have also been reported. Economic challenges have been cited as impacting performance.

Health In Tech, Inc. is an AI-powered insurance technology platform company that offers a health insurance marketplace focused on self-funded benefits plans and stop loss insurance. The company leverages AI and machine learning to streamline underwriting, quoting, and sales processes, significantly reducing the time and complexity traditionally associated with these activities. HIT's platform serves insurance companies, licensed brokers, MGUs, and TPAs, providing customizable health benefits plans and network services. The company operates through three subsidiaries: Stone Mountain Risk (SMR), International Captive Exchange (ICE), and HI Card LLC, each contributing to the overall service offering. HIT's technology enables rapid generation of bindable quotes, often within two minutes, and provides a comprehensive healthcare management platform through HI Card. The company targets small to mid-sized employers, aiming to democratize access to affordable, flexible health insurance solutions. As of December 31, 2025, HIT had a broad client base across 40 states and reported significant revenue growth and profitability [S1].

Tron Inc. is a publicly traded company that has transformed from SRM Entertainment, Inc. into a blockchain-integrated treasury strategy company with a focus on TRX tokens, the native token of the TRON blockchain. Incorporated in Nevada in 2022, the company operates two main businesses: a toy and souvenir segment and a digital asset treasury segment. The toy and souvenir business designs and manufactures licensed merchandise for major theme parks worldwide, leveraging popular entertainment franchises. The digital asset treasury strategy involves accumulating and staking TRX tokens to generate yield through decentralized finance protocols. The company’s treasury wallet is self-managed and secured with regulated custodial services. Tron Inc. has engaged in significant capital raising activities to support its TRX token acquisitions and strategic initiatives. The company’s financials for 2025 reflect a net loss and negative earnings per share, with a strong current ratio indicating liquidity. The company faces risks related to token price volatility, regulatory uncertainties, and operational challenges in its merchandise business.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, particularly breast cancer and related conditions. Its lead product candidate, (Z)-endoxifen, is an oral selective estrogen receptor modulator/degrader in Phase 2 clinical development. The company is exploring multiple indications for (Z)-endoxifen, including breast cancer risk reduction, treatment of ER+/HER2- breast cancer, and rare diseases such as Duchenne Muscular Dystrophy and McCune-Albright Syndrome. (Z)-endoxifen is patented in the U.S. and internationally with protection through at least 2038. The company conducts several Phase 2 clinical trials evaluating efficacy and safety across different patient populations and treatment settings. Atossa has received FDA orphan drug designations for (Z)-endoxifen in DMD. Financially, the company reported a net loss of $34.8 million for 2025 and held $41.3 million in cash at year-end, with strong liquidity ratios. The company has no current revenue and depends on capital raises to fund operations. It also recently completed a reverse stock split to regain Nasdaq compliance.

Immix Biopharma, Inc. focuses on developing next-generation CAR-T cell therapies for serious diseases, with a lead candidate NXC-201 targeting relapsed/refractory AL Amyloidosis. The company’s N-GENIUS platform supports the design and manufacture of its cell therapies. NXC-201 is in Phase 1b/2 clinical trials in the U.S. and ex-U.S., with plans for a Biologics License Application submission following trial completion. The therapy has received FDA Breakthrough Therapy, RMAT, and Orphan Drug Designations, reflecting regulatory recognition of its potential. Immix has demonstrated positive clinical responses and a favorable safety profile in interim data. The company outsources manufacturing to contract organizations and has expanded clinical trial sites nationwide. Immix has raised capital through equity offerings and grants to support its development programs but continues to operate at a net loss with no approved products or revenues to date.

Axiom Intelligence Acquisition Corp 1 is a Cayman Islands exempted blank check company incorporated in January 2025. Its sole purpose is to identify and complete an initial business combination with one or more businesses or entities in any industry. The company completed its IPO in June 2025, raising $200 million, and simultaneously completed a private placement raising $6 million. The proceeds, except for working capital, are held in a trust account. The company has not generated operating revenues and has not yet entered into a definitive agreement for a business combination. The management team, led by experienced executives, is responsible for sourcing and completing the business combination, with a focus on European infrastructure sectors such as energy, digital, and transportation. The company must complete the business combination by June 20, 2027, or liquidate and return funds to shareholders. It may raise additional financing to complete the combination, which could dilute existing shareholders. The company maintains strong liquidity as of the latest fiscal year end.

Lionheart Holdings is a Cayman Islands exempted blank check company (SPAC) incorporated in February 2024. Its business objective is to identify and complete a business combination with one or more established businesses that have proven unit economics, capable management teams, and defensible market positions. The company completed its IPO in June 2024, raising $230 million, which is held in a trust account to fund the business combination. The company has no operating revenues or business operations prior to the business combination and must complete the transaction by June 20, 2026, or liquidate and return funds to shareholders. The management team leverages a broad network and proprietary deal flow to source potential targets. The company’s financial snapshot as of December 31, 2025, shows strong liquidity with a current ratio of 5.1 but no operating results. The company faces competition from other SPACs and investment groups in sourcing targets and has substantial doubt about its ability to continue as a going concern without completing a business combination or securing additional financing [S1][S2].

Finward Bancorp, incorporated in 1994, is the holding company for Peoples Bank, an Indiana-chartered commercial bank. The Bank operates 26 branches primarily serving Lake and Porter Counties in Northwest Indiana and Cook County, Illinois. Its core business involves attracting deposits and originating loans secured by residential and commercial real estate, construction, consumer, commercial business, and municipal loans. The Company also offers wealth management services including estate and retirement planning and trust services. The Bank's deposit accounts are insured by the FDIC, and the Company is regulated by the Federal Reserve Board, with the Bank also regulated by the FDIC and Indiana Department of Financial Institutions. The Company reports all operations as a single segment. As of December 31, 2025, total assets were approximately $2.0 billion, with loans receivable net of deferred fees and costs of $1.45 billion and deposits of $1.7 billion. The loan portfolio is diversified, with commercial real estate loans comprising the largest segment. The Company maintains a Board-approved appraisal policy for commercial loans and actively manages credit quality. Liquidity is supported by deposits, loan repayments, securities, and borrowing capacity from Federal Home Loan Bank and Federal Reserve facilities. The Company has a memorandum of understanding with regulators that includes restrictions on dividend payments without prior approval.

Stardust Power Inc. is a development-stage lithium refinery company formed in 2023, focused on constructing a battery-grade lithium carbonate (BGLC) refinery in Muskogee, Oklahoma. The refinery is designed to produce up to 50,000 metric tons per annum of BGLC, targeting the U.S. domestic market, including battery manufacturers, defense, and OEMs. The company employs a hub-and-spoke model sourcing lithium chloride feedstock from multiple brine suppliers across the Americas, aiming to reduce supply risk and cost. It has secured land for the facility, engaged engineering firms Hatch and Primero for project readiness and front-end engineering, and raised capital through public offerings and convertible debt. The company has not yet commenced production or sales and reported significant net losses and liquidity constraints as of the end of 2025. Stardust Power benefits from potential state and federal incentives and aims to contribute to U.S. energy independence and supply chain security in the lithium sector.

Central Bancompany, Inc. operates as a bank holding company with a focus on banking and financial services primarily in Missouri and surrounding markets. The company is regulated by the Federal Reserve and other federal and state agencies, requiring compliance with capital adequacy standards under Basel III and other regulatory frameworks. It provides a range of banking products and services, including loan origination, deposit accounts, and wealth management services. The company is engaged in modernizing its core banking technology infrastructure and has introduced new AI-enabled financial management tools. It faces competition from larger, better-capitalized financial institutions and is subject to risks related to geographic concentration, regulatory compliance, and technological change.

DT Cloud Star Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in late 2022. It raised gross proceeds of $69 million through an IPO in July 2024, with additional private placement proceeds. The company’s units trade on Nasdaq under the symbol DTSQU, with ordinary shares and rights trading separately under DTSQ and DTSQR. The company’s purpose is to identify and complete a business combination with a target business, leveraging its management team’s experience and network. The management team is led by CEO Sam Zheng Sun, who has a background in private equity and venture capital in Asia. The company’s acquisition strategy is broad, targeting businesses with strong market positions, recurring revenue, and growth potential, without industry or geographic restrictions. It entered into a business combination agreement with PrimeGen US, Inc., a biotech firm, in February 2026. The company’s financial position as of December 31, 2025, shows limited cash and a low current ratio, reflecting its SPAC status. The company has no operating history or revenues and will generate revenues only after consummating a business combination.

Keen Vision Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) incorporated in the British Virgin Islands in 2021. It completed its IPO in July 2023, raising net proceeds of approximately $151 million, which are held in a trust account invested primarily in U.S. Treasury securities and money market funds. The company’s management team has extensive experience in private equity, de-SPAC transactions, and corporate finance, focusing on identifying a growth-oriented target in the biotech, consumer goods, or agriculture sectors with strong ESG considerations. KVAC has entered into a letter of intent with Medera and its subsidiary Novoheart for a potential business combination centered on pre-clinical human disease modeling and drug discovery. The company’s financial position as of December 31, 2025, shows limited operating cash but significant trust account assets. The company’s acquisition strategy emphasizes rigorous due diligence, operational improvements, and leveraging capital markets access post-combination.

ServiceTitan, Inc. provides a comprehensive cloud-based software platform designed specifically for the trades industry, which encompasses field service activities for residential and commercial infrastructure. The platform supports critical business functions including customer relationship management, field service management, enterprise resource planning, human capital management, and financial technology services. ServiceTitan's software is deeply embedded in its customers' operations, enabling automation and data-driven insights to improve business outcomes. The company generates revenue primarily through subscription fees and usage-based fees linked to the size and activity of its customers' businesses. ServiceTitan has experienced rapid growth in revenue and employee headcount, with a focus on expanding product offerings, including AI-powered features, and geographic reach. The company operates internationally and maintains strong liquidity to support ongoing investments and operations [S1].

JBS N.V. is the world's largest protein company by net revenue, operating a global platform that prepares and delivers a wide range of protein products including beef, poultry, pork, lamb, fish, and eggs. The company has significant processing capacities across multiple continents, including the largest global capacities in beef and poultry production. Its products are marketed under numerous well-known brands across North America, Brazil, Australia, and Europe. JBS operates through seven reportable segments and serves over 330,000 customers worldwide. The company generates the majority of its revenue domestically in countries where it operates facilities, with a substantial portion from exports, particularly to Asia, Africa, and the Middle East. JBS has made strategic investments to expand its production capabilities and diversify geographically, including new facilities in the US and a multiprotein platform in Oman. The company maintains a strong liquidity position and a well-staggered debt maturity profile, supported by cash flows from operations and credit facilities.

Polyrizon Ltd. develops innovative medical device hydrogels delivered as nasal sprays that form a physical barrier in the nasal cavity to block viruses and allergens. The company’s proprietary C&C technology acts as a "biological mask" by creating a thin hydrogel shield, while the T&T platform focuses on sustained intranasal delivery of active pharmaceutical ingredients (APIs). The C&C product candidates, including NASARIX™ (PL-14) for nasal allergies and PL-16 for influenza, are positioned as Class II medical devices regulated by the FDA, with NASARIX™ pursuing 510(k) clearance and PL-16 pursuing De Novo classification. The T&T platform targets delivery of corticosteroids, benzodiazepines, and naloxone, with feasibility studies underway and clinical trials planned. Polyrizon operates primarily in Israel and holds an exclusive license from SciSparc Ltd. for the SCI-160 platform related to pain treatment. The company reported a net loss for the fiscal year ending 2025 and maintains a strong liquidity position. Recent news highlights include strategic acquisition plans and clinical development milestones.

Marex Group plc is a global financial services firm providing market access, infrastructure, and liquidity services across commodity and financial markets. Incorporated in England and Wales, Marex operates through four interconnected business segments: Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions. Clearing connects clients to over 60 exchanges worldwide, acting as principal and generating commission revenue. Agency and Execution offers liquidity primarily in energy and financial securities markets, while Market Making provides direct market pricing across multiple asset classes with revenue from bid-ask spreads. Hedging and Investment Solutions delivers bespoke hedging products to manage commodity and currency risks. The company serves over 3,400 active clients including commodity producers, traders, banks, and asset managers, supported by more than 3,000 employees globally. Marex has expanded through acquisitions such as Valcourt SA and Webb Traders to enhance its fixed income and equity derivatives offerings. The company’s financial performance is influenced by commodity price volatility, economic conditions, geopolitical events, and interest rate changes. Marex maintains regulatory capital and liquidity requirements under UK IFPR and manages risks related to market volatility, regulatory compliance, and acquisition integration.

COSCIENS Biopharma Inc. develops and commercializes natural active ingredients primarily derived from oats, targeting personal care, cosmetic, human, and animal health markets. The company uses proprietary technologies such as Ethanol Fractionation Processes and licensed PGX Technology to produce bioactive ingredients. The PGX Technology enables advanced processing of biopolymers into novel materials with applications across functional foods, nutraceuticals, cosmeceuticals, and pharmaceuticals. COSCIENS historically operated a biopharmaceutical segment focused on Macrilen®, an FDA and EMA approved diagnostic test, but this segment is being wound down due to clinical setbacks and insolvency of German subsidiaries. The company sells mainly through distribution networks, minimizing direct sales and marketing expenses. COSCIENS is implementing cost-saving strategies including delisting from Nasdaq and plans to suspend SEC reporting obligations. Financially, the company reported $7.5 million revenue and a net loss of $10.4 million for 2025, with cash reserves supporting operations into 2027 [S1][N1][N2][N3].

Texas Community Bancshares, Inc. is a Maryland-based bank holding company for Broadstreet Bank, SSB, a Texas-chartered savings bank headquartered in Mineola, Texas. The company provides a range of banking services including residential and commercial real estate loans, construction loans, municipality loans, commercial and consumer loans, and invests in various securities. Its primary market area covers several counties in Texas including Mineola and the Dallas-Fort Worth Metroplex. The company operates under regulatory oversight from the Federal Reserve Board, Texas Department of Savings and Mortgage Lending, and the FDIC. It offers deposit products such as checking, savings, money market, and certificates of deposit. The company faces competition from a variety of financial institutions in its local market.

MaxCyte, Inc. operates as a commercial cell engineering company focused on enabling platform technologies to advance discovery, development, and commercialization of next-generation cell therapeutics, including cell and gene therapies. The company’s core technology is its proprietary Flow Electroporation® platform, which facilitates the delivery of molecules such as DNA, mRNA, siRNA, and proteins into a wide variety of eukaryotic cells with high efficiency, viability, and reproducibility. The ExPERT platform comprises five instruments (DTx, ATx, STx, GTx, VLx) and a portfolio of proprietary processing assemblies (PAs) and consumables, designed to support scalable cell engineering from research through cGMP manufacturing. MaxCyte’s technology is used by leading biopharmaceutical companies, academic institutions, and government agencies, including the NIH. The company’s business model includes sales of instruments, disposables, consumables, annual license fees, and milestone and sales-based payments under strategic partner license agreements. MaxCyte acquired SeQure Dx in January 2025 to expand its gene editing assessment services. The company maintains a robust intellectual property portfolio and quality management system compliant with ISO 9001:2015 standards. As of December 31, 2025, MaxCyte had strong liquidity with $20.07 million in cash and $82.98 million in short-term investments, a current ratio of 8.3, and reported $33.03 million in revenue and a net loss of $44.63 million for the fiscal year 2025.

BeyondSpring Inc. develops innovative cancer therapies with a focus on its lead drug candidate Plinabulin, which is being tested in multiple cancer indications including metastatic NSCLC. The company also operates a targeted protein degradation (TPD) platform through its subsidiary SEED Therapeutics, which it has been divesting since late 2024. BeyondSpring’s business model includes clinical development, strategic collaborations, and equity investments in subsidiaries. The company’s financials show ongoing research and development expenses, moderate liquidity, and net losses consistent with a clinical-stage biopharmaceutical company. Its operations span the U.S. and China, with offices in New Jersey and Beijing/Dalian. BeyondSpring’s recent news and SEC filings provide updates on clinical progress, financial transactions, and corporate strategy.

Cognyte Software Ltd. was spun off from Verint in 2021 and focuses on providing cybersecurity software solutions, particularly in investigative analytics and cyber intelligence. The company generates revenue through software sales, software services including support and SaaS subscriptions, and professional services such as deployment and consulting. Cognyte operates globally with significant revenue contributions from EMEA, Americas, and APAC regions. The company invests heavily in research and development and maintains a strong liquidity position. Management and board members have extensive experience in cybersecurity and technology sectors. Cognyte has engaged in strategic acquisitions and share repurchase programs to support growth and shareholder value.

Foresight Autonomous Holdings Ltd. develops advanced stereoscopic 3D perception systems and cellular-based vehicle-to-everything (V2X) safety applications. Its technology mimics human depth perception using synchronized cameras to create dense 3D point clouds, applicable across automotive, defense, agriculture, industrial equipment, urban rail, and unmanned aerial vehicles. The company operates through subsidiaries including Foresight Automotive and Eye-Net Mobile, the latter focusing on AI-driven V2X collision prevention solutions delivering real-time alerts via smartphones and smart devices. Foresight's products address challenges in autonomous driving such as obstacle detection in diverse and adverse conditions, supporting higher levels of vehicle automation. The company has established strategic partnerships and joint ventures globally to advance commercialization and technology deployment in key markets.